timothy sykes logo
PBM Stock Surges As Psyence BioMed Rides Psychedelic Tailwinds Thumbnail
ADD US ONG Google News

PBM Stock Surges As Psyence BioMed Rides Psychedelic Tailwinds

TIM SYKES•UPDATED APR. 17, 2026, 9:18 AM ET
Reviewed by Bryce Tuohey Fact-checked by Matt Monaco

Psyence Biomedical Ltd. stocks have been trading up by 70.53 percent amid heightened optimism over its psychedelic therapeutics pipeline.

Candlestick Chart

Live Update At 09:18:22 EDT: On Friday, April 17, 2026 Psyence Biomedical Ltd. stock [NASDAQ: PBM] is trending up by 70.53%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

PBM has gone from a quiet grinder to a full-on momentum play. Over the past few weeks, Psyence Biomedical Ltd. mostly chopped between roughly $2.35 and $2.65, with closes inching higher but not screaming. Then, on 2026/04/16, PBM exploded from an open around $2.81 to a high near $9.97, closing at $5.87. That is a massive range and a clear signal of speculative money piling in.

Intraday, the 5-minute chart shows heavy volatility, with PBM trading from the $8s up into the low $12s before settling back around $10. That’s textbook high-beta action. For traders, this means plenty of liquidity and range, but also the need to control risk with tight plans.

Fundamentally, Psyence BioMed is still a pre-revenue-style psychedelic biotech story. The balance sheet shows roughly $6.17M in cash and total assets of about $7.32M as of 2025/03/31, offset by modest liabilities near $0.59M. Book value per share sits around 6.58, while PBM trades below that, implying the market has not fully priced in the pipeline yet. Add negative returns on assets and capital, and the picture is clear: this is a development-stage name where trial progress and policy news drive the tape more than earnings.

Why Traders Are Watching PBM Right Now

This move in PBM is not random. Psyence Biomedical Ltd. is sitting at the intersection of two powerful forces: a shifting U.S. policy backdrop for psychedelics and tangible clinical progress with its own psilocybin program.

On the macro side, the Trump administration preparing an executive order to promote federal research into ibogaine is a big sector signal. Ibogaine is being studied abroad for PTSD, depression, anxiety, addiction, and brain trauma. When the U.S. starts talking about federal research support, traders listen. That policy hint has already pushed psychedelic-focused biotech names higher, and PBM has been one of the beneficiaries.

For traders, this matters because broader regulatory support often leads to more research dollars, easier trial design, and a more open path to eventual approvals. Psyence Biomedical Ltd. does not work on ibogaine specifically in this news, but it plays in the same sandbox. PBM gets pulled along as traders re-rate the entire psychedelic complex on the possibility of a friendlier environment.

At the company level, Psyence BioMed is also delivering its own catalyst: expanding the Australian Phase IIb trial of NPX-5 from three to five clinical sites. Adding Ramsay Health Care and NeuroCentrix should speed up patient enrollment in palliative oncology patients with Adjustment Disorder and tighten the timeline to meaningful data. That is the type of operational progress traders hunt in small-cap biotech.

PBM is also leaning on its own GMP-manufactured NPX-5 supply, which helps de-risk logistics and shows Psyence Biomedical is thinking ahead about scale and quality. Combined with the regulatory tailwind, these company-specific advances explain why PBM has suddenly turned into a hot trading ticker.

More Breaking News

Conclusion

Psyence Biomedical Ltd. is a classic high-risk, high-reward biotech story that just woke up on the chart. PBM has a clean but early-stage balance sheet, a negative return profile typical of pre-commercial biotechs, and a pipeline that now sits in the market’s spotlight. The violent price action off the recent lows shows traders are repositioning around two key ideas: a friendlier U.S. stance toward psychedelics and accelerating NPX-5 clinical work in Australia.

For active traders, PBM is not about steady cash flows; it is about catalysts and timing. The ibogaine executive-order chatter tells the market that Washington is starting to take psychedelic science more seriously. At the same time, Psyence BioMed is quietly building a larger trial footprint, aiming for faster data and a stronger story around NPX-5 in palliative oncology patients.

That combination of macro tailwind and micro execution is what often fuels parabolic runs in small biotech names. But with big range comes big risk. As Tim Sykes likes to say, “The market rewards preparation, not hope — study the pattern, know the catalyst, and always, always cut losses quickly.” As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. PBM gives traders a live case study in that mindset: respect the momentum, understand the story, and let risk management drive every trade. This analysis is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading PBM

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”